2007 NSTI Nanotechnology Conference and Trade Show - Nanotech 2007 - 10th Annual

Development of Targeted Nanoparticles for Prostate Cancer Therapy In Vivo

E. Levy-Nissenbaum, F. Alexis, B.A. Teply, J. Cheng, F.X. Gu, A.F. Radovic-Moreno, R. Langer and O.C. Farokhzad
Massachusetts Institute of Technology and Brigham & Women's Hospital, Harvard Medical School, US

nanoparticle, Aptamer, Targeted, Prostate, Cancer, Controlled Release

Targeted drug delivery platforms rely on the availability of high affinity ligands against tumor-specific or tumor-associated antigens to specifically deliver a cytotoxic payload to a subset of cells. In the case of cancer, there is a substantial inter- and intra-tumoral heterogeneity in the pattern of antigen expression that makes targeting one antigen of limited value. Furthermore, the ideal tumor-antigen should be rapidly internalized to allow for the efficient uptake of targeted nanoparticles that recognize these antigens for maximal therapeutic efficacy. We have developed targeted nanoparticles that are efficiently taken up by prostate cancer cells in vitro and in vivo, resulting in remarkable efficacy against this cancer using mouse models of prostate cancer. We have also isolated novel nucleic acid ligands (referred to as aptamers) against prostate cancer antigens that allow for the development of multi-antigen targeted nanoparticles for the treatment of prostate cancer. These vehicles are expected to have therapeutic utility for majority of patient’s with this disease given the overlapping pattern of targeting that is conferred by the virtue of having distinct ligands against more than one antigen. We believe that similar approaches may be used to develop targeted nanoparticles against other important human diseases, such as other cancers.

Back to Program

Sessions Sunday Monday Tuesday Wednesday Thursday Authors Keywords

Nanotech 2007 Conference Program Abstract


Names, and logos of other organizations are the property of those organizations and not of NSTI.
This event is not open to the general public and NSTI reserves the right to refuse admission and participation to any individual.